Sign In
Buy ORGO
$2.33
+0.0900 (+4.02%)
At Close: Jun 03, 2026
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis
07:00am, Thursday, 02'nd May 2024
CANTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pr
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
07:30am, Tuesday, 16'th Apr 2024
CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case
07:30am, Wednesday, 03'rd Apr 2024
CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of p
Why Organogenesis Holding Stock Plummeted by 18% Today
06:29pm, Friday, 01'st Mar 2024
To put it charitably, the market wasn't impressed with the company's recent performance. They traded out of the stock following the publication of quarterly and annual results.
Organogenesis Holdings, Inc. (ORGO) Q4 2023 Earnings Call Transcript
11:06pm, Thursday, 29'th Feb 2024
Organogenesis Holdings, Inc. (ORGO) Q4 2023 Earnings Call Transcript
Organogenesis (ORGO) Reports Break-Even Earnings for Q4
06:46pm, Thursday, 29'th Feb 2024
Organogenesis (ORGO) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.06 per share a year ago.
Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance
04:05pm, Thursday, 29'th Feb 2024
CANTON, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p
CANTON, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024
04:05pm, Thursday, 08'th Feb 2024
CANTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p
Are You Looking for a Top Momentum Pick? Why Organogenesis (ORGO) is a Great Choice
01:32pm, Monday, 15'th Jan 2024
Does Organogenesis (ORGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Best Momentum Stocks to Buy for January 5th
11:17am, Friday, 05'th Jan 2024
ORGO, CALM and NET made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 5, 2024.
New Strong Buy Stocks for January 5th
08:16am, Friday, 05'th Jan 2024
ORGO, CALM, W, NET and EVH have been added to the Zacks Rank #1 (Strong Buy) List on January 5, 2024.
Organogenesis (ORGO) is a Great Momentum Stock: Should You Buy?
01:32pm, Thursday, 28'th Dec 2023
Does Organogenesis (ORGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Reasons Why Small-Cap Stocks Can Surge in 2024: 5 Top Picks
09:46am, Friday, 15'th Dec 2023
Small-cap stocks should rally ahead due to cheaper valuation, cooling inflation data and hopes of Fed rate cuts in 2024. Against this backdrop, Organogenesis (ORGO), Riskified (RSKD), Hooker Furniture
NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Organogenesis Holdings, Inc. (NASDAQ: ORGO)
